This Combination Therapy Could Help Change Cancer Treatment - Take A Deeper Look Into Allarity Therapeutics' Trial - Seite 2

The first stage of the trial will dose patients with stenoparib twice daily to examine the maximum tolerated dose (MTD) of the drug in patients with advanced solid tumors. The second stage of the trial will determine the MTD of dovitinib when given in conjunction with the MTD of stenoparib. The trial will also use Allarity Therapeutics' DRP companion diagnostics to retrospectively identify responders to the treatment. The study is also designed to assess early signals of a therapeutic benefit of the combination of drugs.

According to Dr. Mirza, this combination has the potential to be particularly efficacious, and the study will be looking at whether these drugs cause synthetic lethality for the tumor. If these trials are safe and effective, then there is the potential for holding comparative trials that measure this combination therapy against traditional treatments like chemotherapy, which can be highly toxic.

Dr. Mirza stated, "In the battle against cancer, we must relentlessly seek innovative and effective therapies. New unique combination therapies have the potential to significantly alter the landscape of cancer treatment. The combination study of stenoparib and dovitinib is interesting because of a variety of reasons, but one I personally find very appealing with such novel combinations is that they could offer a chemotherapy-free treatment option, for example, in our treatment of ovarian cancer patients. Avoiding the side effects typically associated with chemotherapy would be a very welcomed treatment option."

The Principal Investigator for Allarity's Phase 1b study, Kathleen N. Moore, MD, MS, commented: "I look forward to working with patients and the clinical team at Allarity to determine if the particular combination of dovitinib and stenoparib can provide synergistic therapeutic benefits and improve outcomes for patients, including those with ovarian cancer." Dr. Moore is a Gynecologic Oncology faculty member at the University of Oklahoma College of Medicine and Associate Director of Clinical Research at the Stephenson Cancer Center.

Allarity Therapeutics also has two ongoing, phase two monotherapy trials for its drugs Dovinitinb and Stenoparib. The company anticipates interim data readouts from these trials to come in late 2023. Other companies investigating treatments for hard-to-treat cancers include Soligenix and Salarius Pharmaceuticals.

To learn more about what Allarity Therapeutics is doing to battle cancer and look to realize truly personalized cancer care, visit its website.

Featured photo by National Cancer Institute on Unsplash

US investor contact:

Thomas Jensen
[e-mail]
[phone]

EU investor contact:

Thomas Pedersen
[e-mail]
[phone]

SOURCE: Allarity Therapeutics

View source version on accesswire.com:
https://www.accesswire.com/749494/This-Combination-Therapy-Could-Help- ...


The Allarity Therapeutics Stock at the time of publication of the news with a raise of +27,93 % to 1,420USD on NYSE stock exchange (15. April 2023, 02:00 Uhr).